SCHEMBL5174282

SCHEMBL5174282

O=C(O)CN1CCN(c2ccccn2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.71
THRB P10828 1/20 0.71
HTR1A P08908 1/20 0.64
KDM4E B2RXH2 3/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2C9 P11712 1/20 0.63
HPGD P15428 1/20 0.63
RECQL P46063 1/20 0.63
HSD17B10 Q99714 1/20 0.63
ALDH1A1 P00352 8/20 0.62
LMNA P02545 3/20 0.62
GAA P10253 2/20 0.62
MAPT P10636 2/20 0.61
DRD2 P14416 2/20 0.61
DRD4 P21917 2/20 0.61
POLB P06746 2/20 0.61
TSHR P16473 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
DRD3 P35462 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1373101 0.98 NPSR1 (0.69) NPSR1THRBHTR1AKDM4ECYP3A4
SCHEMBL10403767 0.88 THRB (0.67) NPSR1THRBHTR1AKDM4EHSD17B10
SCHEMBL10772825 0.86 THRB (0.65) NPSR1THRBHTR1AKDM4EHSD17B10
SCHEMBL5544596 0.86 THRB (0.65) NPSR1THRBHTR1AKDM4EALDH1A1
SCHEMBL4405017 0.86 THRB (0.65) NPSR1THRBHTR1AKDM4EHSD17B10
SCHEMBL5009465 0.85 HTR1A (0.78) NPSR1THRBHTR1AKDM4ECYP3A4
SCHEMBL6360940 0.84 THRB (0.63) NPSR1THRBHTR1AKDM4EALDH1A1
SCHEMBL4008925 0.83 THRB (1.00) NPSR1THRBKDM4EHSD17B10ALDH1A1
SCHEMBL9080030 0.82 HTR1A (0.61) NPSR1THRBHTR1AKDM4ECYP3A4
SCHEMBL4010416 0.81 POLB (0.84) NPSR1THRBKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1238974-B1 HETEROCYCLE DERIVATIVES AND DRUGS NIPPON SHINYAKU CO LTD (JP) 2007-05-23 EP disclosed
US-6787546-B2 POTENT ANTICANCER ACTIVITY; WATER SOLUBLE; INJECTION 4-(2-(2-(N-(4-METHOXYBENZENESULFONYL)-N -PIPERIDINOACETYLAMINO)PHENYL)ETHENYL)PYRIDINE 1-OXIDE HYDROCHLORIDE NIPPON SHINYAKU CO., LTD. (JP) 2004-09-07 US disclosed
US-20030022884-A1 Heterocycle derivatives and drugs NIPPON SHINYAKU CO., LTD. (JP) 2003-01-30 US disclosed
EP-1238974-A1 HETEROCYCLE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2002-09-11 EP disclosed
US-4914206-A ANTIBIOTICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-04-03 US disclosed
EP-0226896-A2 Lankacidin derivatives and production thereof Takeda Chemical Industries, Ltd. (JP) 1987-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022884-A1 Heterocycle derivatives and drugs ABCC5, CYP3A5, CYP2D6 NPSR1 153/4885THRB 2921/4885HTR1A 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.